An important obstacle to fight better diabetic retinopathy is the use of a classification based on old imaging techniques insufficient to finely predict the evolution of the disease. New imaging techniques (including ultra widefield fundus photography, optical coherence tomography, OCT-angiography) are already available. They generate vast new valuable data, that combined with other data and with a new adapted classification can provide a more accurate evaluation of diabetic retinopathy risks. This will be the based to the development of a more personalized preventive treatment that can help maintain the full vision of diabetic patients.
Our difference is to use new technologies to develop a medical decision support tool.
The combination of diabetology and ophthalmology knowledge, industrial R&D and academics skills, large cohort of patients with companies that are already world class leaders creates a unique opportunity to make this project a success.
We will use a unique combination of clinical information of patients, the best modalities of retinal imaging, and our home-made artificial intelligence to provide ophthalmologists with a decision aid tool for improved diagnosis and risk evaluation, allowing them to take an easier, quicker, and better decision for their patients. Per design, instead of increasing costs and inequity EviRed should help reducing unnecessary treatment or burden and ease the spread of expertise to where it is needed.
Database 1 is the first of EviRed clinical trials.
Aim: To recruit a cohort of 5000 patients, in 10 different French sites scattered across the country, and follow them for at least 2 years to collect data needed to train and validate developed algorithms.
They participate and recruit for the project Evired DataBase 1
Sponsor: Assistance Publique – Hôpitaux de Paris (AP-HP)
|001- CHU LARIBOISIERE||PARIS||Aude COUTURIER|
|002 - CHU DIJON||DIJON||Catherine CREUZOT-GARCHER|
|003 - CHU BORDEAUX||BORDEAUX||Jean-François KOROBELNIK|
|004 - CHU LYON CROIX ROUSSE||LYON||Laurent KODJIKIAN|
|005 - CHU AVICENNE||BOBIGNY||Audrey GIOCANTI|
|006 - CIC CRETEIL||CRÉTEIL||Alexandra MIERE|
|007 - CHU PITIE||PARIS||Sarah TOUHAMI|
|008 – BROCA / MUTUELLE GENERALE||PARIS||Pascale MASSIN|
|009 - CHU BREST||BREST||Béatrice COCHENER|
|010 - HÔPITAL DES 15-20||PARIS||Sarah AYELLO- SCHEER|
|011 - CHU NANTES||NANTES||Michel WEBER|
|012 - FONDATION ROTHSCHILD||PARIS||Sophie BONNIN|
|013 - CENTRE MONTICELLI PARADIS||MARSEILLE||Pierre GASCON|
|014 - CHU NICE||NICE||Stéphanie BAILLIF|
Thomas W. Gardner, is Professor of Ophthalmology and Visual Sciences, of Internal Medicine (Metabolism, Endocrinology and Diabetes) and of Molecular and Integrative Physiology. He is working for the University of Michigan Kellog Eye Center in Ann Arbor working at the University of Michigan. His main interests include clinical and experimental diabetic retinopathy as well as vitreoretinal diseases and surgery.
Professor Pearse Keane is a retinal specialist at Moorfields Eye Hospital in London, UK, and Professor of Artificial Medical Intelligence at University College London (UCL). He is working on developing artificial intelligence (AI) algorithms and their application in detection and treatment of retinal diseases.
Doctor Richard Spaide is in private practice at the Vitreous, Retina, Macula Consultants of New York. He is specialized in retinal diseases and focused his researches on imaging methods (OCT, OCT-A). He has also developed surgical ophthalmic instruments. He is the first author with the most highly cited articles in the top 100 list published between 2010 and 2020.
Professor Adnan Tufail is based at Moorfields Eye Hospital and at Institute of Ophthalmology at UCL (University College London), he specialized in medical retina disorders (AMD, diabetic retinopathy and myopic degeneration) and cataract surgery.
Nadia Waheed is Professor of Ophthalmology and Director of OCT research at Tufts University School of Medicine in Boston, USA and is the Chief Medical Officer Gyroscope Therapeutics. Her research is focused on novel imaging modalities (OCT, OCT-A) and their applications in AMD and Diabetic Retinopathy, development of endpoints for clinical trials, as well as gene therapy in ocular disease.
Professor Sebastian Wolf is the chairman of the Department of Ophthalmology in Inselspital at University of Bern, Switzerland. His main areas of researches are age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, imaging and vitreoretinal surgery. He is also Director of the Bern Photographic Reading Center.
Dr Jean Zetlaoui is now a consultant in Medical Sciences & Clinical Development. He started his career as Associate Professor in Anaesthesiology & Intensive Care, and then occupied several managing positions in international companies (Sanofi, Nestlé Health Science, Novartis…). He knows well the French healthcare environment and its challenges.
EviRed is also the base for ancillary studies.